Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2012

View Archived Issues

New approach for the rational and automated design of ligands against multiple drug targets

Sunovion Pharmaceuticals synthesizes new mGlu5 receptor modulators

Neuren Pharmaceuticals to conduct phase II trial of NNZ-2566 in Rett syndrome

U.K. researchers develop novel model of B-cell and myeloid malignancies

Forest and Glenmark to develop agents for chronic inflammatory conditions

Takeda and Amylin terminate worldwide agreement

AMAG Pharmaceuticals files sNDA for Feraheme

Favorable results presented for BC-2059, a novel beta-catenin inhibitor

NewGen Therapeutics discloses novel PARP-1 inhibitors

Japanese researchers patent new insulin secretagogues

Infinity Pharmaceuticals amends license agreement with Millennium

Daiichi Sankyo synthesizes new series of renin inhibitors

Covidien to acquire CV Ingenuity

Bristol-Myers Squibb prepares novel Abeta production inhibitors

Clinical trial notification accepted in Japan for phase I oral rigosertib trial

Study of voclosporin in uveitis does not meet primary endpoint

Ajinomoto Pharmaceuticals and Yoshindo to form joint venture

Otsuka obtains new approvals for carnitine deficiency treatments

Pfizer and Bristol-Myers Squibb obtain Japanese approval for novel anticoagulant

Neupro Patch approved in Japan for Parkinson's disease and restless legs syndrome

Japanese MHLW approves marketing application for Cimzia in RA

Japanese MHLW approves Novo Nordisk's combination therapy for diabetes

ABT-199 demonstrates antitumor activity in patients with NHL

Addex Therapeutics characterizes novel mGlu7 negative allosteric modulator

German researchers develop novel technique to study MM cell engraftment and progression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...